Skip to content
Screener

Total Liabilities at other companies

GPA
General Purpose Acquisition Corp.GPAC
$17.3M-28.7%
Veradermics logo
VeradermicsMANE
$6.72M
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$1.01M
Schering-Plough logo
Schering-PloughSGP
$8.27M
Applied Materials logo
Applied MaterialsAMAT
$16.38B+11.6%
Dollar Tree logo
Dollar TreeDLTR
$10.32B-28.3%

Other financials

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M
Total debt$1.0M
Total equity$454.3M+421%
Total assets$467.8M

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K
Free cash flow-$22.7M-47.8%

Valuation

See full
Market cap$2.32B+107%
Enterprise value$2.08B

Returns & leverage

See full
Return on equity-45.7%
Debt / equity
Current ratio35.8×

Where this comes from

Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 4:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344533

FAQ

What is Hemab Therapeutics Holdings, Inc.'s total liabilities?
Hemab Therapeutics Holdings, Inc. (COAG) reported total liabilities of $13.51M in Q2 2026.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Hemab Therapeutics Holdings, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude